Neuraxis, INC 8-K

What Happened
Neuraxis, Inc. (NRXS) filed an 8-K on April 21, 2026 announcing preliminary, unaudited financial results for the three months ended March 31, 2026. Management expects cash and cash equivalents of approximately $7.1 million as of March 31, 2026, net sales of about $1.6 million (up from ~$0.9M in Q1 2025), gross profit of roughly $1.4 million, and an operating loss of approximately $1.7 million. These figures are preliminary and subject to change as the company completes its quarter-end close and finalizes audited financial statements.

Key Details

• Cash and cash equivalents: ~ $7.1 million as of March 31, 2026.
• Net sales (Q1 2026): ~ $1.6 million vs. ~ $0.9 million for Q1 2025 (year-over-year increase).
• Gross profit (Q1 2026, preliminary): ~ $1.4 million.
• Operating loss (Q1 2026, preliminary): ~ $1.7 million.
• The estimates are preliminary, unaudited, prepared by management, and the independent auditor has not reviewed or audited these amounts.

Why It Matters
These preliminary results show year-over-year revenue growth, but the company remains unprofitable on an operating basis for the quarter. The cash balance provides a snapshot of liquidity as of March 31, 2026. Investors should note these are management estimates and may change when final, audited quarterly financial statements and disclosures are completed.